Details for Patent: 5,403,856

United States Patent 5,403,856: Scope, Claim Boundaries, and US Landscape for S-Enantiomer ACE Inhibitors in Cardiac Insufficiency

What does US 5,403,856 claim, in operational terms?

US 5,403,856 is directed to methods for treating cardiac insufficiency in a mammal using an angiotensin-converting enzyme (ACE) inhibitor defined by a specific stereochemical and structural constraint.

Core claim 1 elements (the actual scope driver)

Claim 1 requires all of the following:

1. Use / purpose
   • “A method for treating cardiac insufficiency in a mammal”
2. Patient population
   • “administering to a mammal in recognized need of” the treatment
3. Drug class
   • “an amount of an angiotensin-converting enzyme inhibitor of the formula I, or a pharmaceutically acceptable salt thereof”
4. Isomer purity
   • the inhibitor or salt is “substantially free of other isomers”
5. Specific formula (Formula I) with defined substituent constraints
   • The patent defines Formula I with:
     • n = 2
     • R = phenyl
     • R1 = methyl
     • R2 = hydrogen, methyl, ethyl or benzyl
     • R3 = hydrogen
     • R4 and R5 together with their atoms form an octahydrocyclopenta[b]pyrrole ring system
6. Absolute stereochemistry
   • “provided that all the chiral atoms … are in the S position”

In effect, claim 1 is a stereochemically narrowed method-of-use tethered to a particular ACE inhibitor scaffold (Formula I) with S,S-only configuration and isomer purity.

Which specific embodiments are locked in by dependent claims?

Dependent claims narrow claim 1 to specific named active substances.

Claim 2 (specific stereochemically defined compound)

• N-(1-S-carbethoxy-3-phenyl-propyl)-S-alanyl-1S,3S,5S-2-azabicyclo[3.3.0]octane-3-carboxylic acid, or salt

Claim 3 (closely related specific compound)

• N-(1-S-carboxy-3-phenyl-propyl)-S-alanyl-1S,3S,5S-2-azabicyclo[3.3.0]octane-3-carboxylic acid, or salt

Claim 4 (route)

• Oral or parenteral administration

Claim 5 (formulation)

• Administration with excipients or acceptable organic/inorganic substances

Claim 6 (dose concept)

• The inhibitor is administered in a “sub-anti-hypertensive dose”

What is the functional claim scope if you are designing around it?

Claim 1 is a compound-linked method claim, so design-around focuses on breaking at least one required limitation: structure, S stereochemistry, isomer purity, ring system, or the dosing/purpose language.

1) S-enantiomer requirement is a hard boundary

• Claim 1 requires all chiral atoms in the S position.
• If a competitor product uses:
  • a racemate,
  • an enriched mixture that is not “substantially free of other isomers,” or
  • any chiral center not exclusively S, then claim 1 is less likely to read (and dependent claim coverage also becomes harder).

2) “Substantially free of other isomers” is a quality-control trigger

• The claim is not just “single stereoisomer”; it also requires a purity standard (“substantially free”).
• For enforceability and infringement analysis, purity is typically analyzed through:
  • enantiomeric excess and stereochemical impurity profile,
  • analytical method comparability,
  • and product release specifications. (Those details are not supplied in the text you provided; the scope point remains that purity is a required element.)

3) Formula I constraints are structural and limiting

• n is fixed at 2.
• R is fixed as phenyl.
• R1 is fixed as methyl.
• R3 is fixed as hydrogen.
• R4 and R5 must form the octahydrocyclopenta[b]pyrrole ring system.
• R2 allows several substituents (H, methyl, ethyl, benzyl), so there is still some substitution freedom inside that boundary.

4) Indication is “cardiac insufficiency”

• The claim’s method-of-use is for cardiac insufficiency in mammals.
• This is not “hypertension” broadly, and it is not “heart failure” textually in your excerpt, but the dosing dependent claim 6 ties the dose to being below an anti-hypertensive level.

5) Dependent claim 6 adds a dose-positioning limitation

• Claim 6 narrows further to sub-anti-hypertensive dosing.
• If a product is dosed at levels intended and labeled for antihypertensive effect, or if the clinical positioning is clearly at antihypertensive dose ranges, claim 6 becomes less relevant. Claim 1 still does not require sub-anti-hypertensive dose, but it does require the formula and stereochemical constraints.

How strong is the protection profile, claim-by-claim?

Claim 1 (strongest independent scope)

• It covers:
  • all Formula I ACE inhibitors (with allowed R2 variants),
  • salts,
  • S stereochemistry at all chiral centers,
  • and an isomer purity requirement,
  • used to treat cardiac insufficiency.
• This is a broad-enough method claim to cover multiple candidates that share the same stereochemically defined scaffold and S-only purity, even if the specific named compound differs within the allowed substituent permutations.

Claims 2 and 3 (narrow embodiments)

• These are specific compounds with tight structural recitations.
• If a competitor uses a different R2 variant or a different substituent placement not covered, claim 2/3 may not read. Claim 1 may still read if the Formula I constraints match.

Claims 4 and 5 (delivery and formulation)

• These are common “no escape” dependent claims in many composition/method patents.
• They do not materially narrow beyond route/formulation typical for drug delivery.
• If a competitor uses the same API but changes route, claim 4 may be avoided, but claim 1 is not limited to oral/parenteral. Claim 5 is similarly non-material if the competitor uses different excipients, because claim 1 stands independently.

Claim 6 (dose concept)

• This claim is more about differentiation than scope capture.
• It can matter for infringement strategy if competitors deliberately dose above or below “sub-anti-hypertensive” thresholds.

Likely patent landscape dynamics in the US (based on claim architecture)

Because the independent claim ties infringement to: 1) a specific stereochemical enantiomer profile and 2) a formula-constrained ACE inhibitor scaffold and 3) a method label for cardiac insufficiency, the US landscape will typically split into three buckets for enforcement and freedom-to-operate (FTO) analysis:

Bucket A: Same scaffold, same S-only purity, cardiac insufficiency use

• Highest infringement risk.
• Any product that uses Formula I ACE inhibitor in S-only form and is used for cardiac insufficiency can fall within claim 1.

Bucket B: Same scaffold but different stereochemistry (mixed isomers, non-S at any chiral center)

• Lower risk against claim 1 because “all chiral atoms… in S position” and “substantially free of other isomers” are gating elements.
• If a competitor sells a non-S or racemic ACE inhibitor, or uses S-enriched but not “substantially free” product, the risk depends on what “substantially free” means in practice for enforcement and how the competitor’s impurity and enantiomer profile are measured.

Bucket C: Same use but different scaffold not matching Formula I constraints

• Avoids claim 1 because structural recitations are limiting.
• Even if another ACE inhibitor treats cardiac insufficiency, it may not read unless it fits Formula I exactly.

Where does the competitive “design space” remain?

Even within Formula I, claim 1 allows multiple possibilities for R2: hydrogen, methyl, ethyl, or benzyl. That means the claim is not confined to one exact R2 substituent.

What remains closed:

• R is phenyl,
• R1 is methyl,
• R3 is hydrogen,
• n is 2,
• ring system is fixed,
• and all chiral centers are S-only.

So product variants that remain in-market under the same scaffold are likely those swapping among the allowed R2 options, while preserving S-only configuration and “substantially free” purity.

Practical infringement map (what to test against)

For any candidate ACE inhibitor intended for cardiac insufficiency, the infringement screening in a US patent portfolio usually reduces to these “pass-fail” tests:

1. Does the candidate match Formula I with n=2, R=phenyl, R1=methyl, R3=H, and the octahydrocyclopenta[b]pyrrole ring system?
2. Are all chiral centers S?
3. Is the product substantially free of other isomers (enantiomeric and diastereomeric purity)?
4. Is it administered “for the purpose” of treating cardiac insufficiency in a mammal?
5. If targeting claim 6 specifically, is dosing positioned as sub-anti-hypertensive?

Key takeaways

• US 5,403,856 is a stereochemically narrowed method-of-treatment patent: it requires Formula I ACE inhibitors with S-only chiral configuration and substantially isomer-pure composition, used to treat cardiac insufficiency.
• Claim 1 is the enforcement backbone: structural Formula I constraints plus stereochemical purity and indication.
• Claims 2 and 3 lock in two specific named compounds falling under Formula I.
• Claims 4 and 5 add route/formulation limitations only as dependents; they do not restrict the core independent scope.
• Claim 6 adds a dosing differentiation point tied to sub-anti-hypertensive use, useful for competitive positioning and infringement defenses.
• Competitive risk concentrates on products that keep the same scaffold and S-only stereochemistry, and on labeling or promotion tied to treating cardiac insufficiency.

FAQs

1. Is this patent limited to a single compound?
No. Claim 1 covers ACE inhibitors of Formula I with defined ring and substituent constraints, as long as the product is S-only and substantially free of other isomers. Claims 2 and 3 add two specific compound examples.

2. Does a competitor avoid infringement by changing the route of administration?
Claim 4 is dependent. Changing from oral to parenteral (or vice versa) can avoid claim 4, but claim 1 still covers the method if the other limitations match.

3. What is the highest-risk technical variable for competitors?
Chiral purity and S configuration at all chiral centers, coupled with matching the Formula I scaffold constraints.

4. Does the patent cover treatment intended for hypertension instead of cardiac insufficiency?
The method is framed for cardiac insufficiency. Claim 6 further ties dosing to sub-anti-hypertensive levels, reinforcing the cardiac-insufficiency treatment strategy.

5. If a product is an ACE inhibitor used for cardiac insufficiency but is not “S-only,” does it still fall under this patent?
Not if it fails the gating requirements in claim 1, which require all chiral atoms in the S position and an inhibitor (or salt) that is substantially free of other isomers.

References

[1] United States Patent 5,403,856. Claims excerpt as provided in the prompt.